arcus-biosciences
(2)
Arcus Biosciences
Arcus built a biotech around a deceptively practical idea: own the pieces of a drug combination before trying to assemble it. After a major TIGIT setback, its next chapter now rests on a kidney-cancer pill, a pancreatic-cancer trial and a careful expansion into inflammation.
Terry Rosen
Terry Rosen is the CEO and co-founder of Arcus Biosciences, a clinical-stage biopharmaceutical company focused on developing combination cancer immunotherapies. A medicinal chemist by training with a Ph.D. from UC Berkeley, Rosen has spent over 30 years at the intersection of chemistry and oncology - from Abbott Laboratories and Pfizer to Amgen, and then co-founding Flexus Biosciences which sold to Bristol-Myers Squibb for $1.25 billion in 2015. He immediately used that platform to launch Arcus, which has since secured a landmark 10-year partnership with Gilead Sciences and advanced multiple molecules into pivotal clinical studies, including casdatifan, a best-in-class HIF-2α inhibitor showing strong results in kidney cancer.